Ultragenyx Q3 2022 Earnings Report
Key Takeaways
Ultragenyx reported a total revenue of $90.7 million for Q3 2022, with Crysvita revenue in Ultragenyx territories reaching $64.5 million. The company reaffirmed its 2022 revenue guidance for Crysvita and Dojolvi. Enrollment completion of DTX401 Phase 3, UX143 Phase 2, and GTX-102 dose escalation cohorts is anticipated around the end of the year.
Total revenue for Q3 2022 was $90.7 million.
Crysvita revenue in Ultragenyx territories was $64.5 million.
Dojolvi product sales were $13.3 million.
Mepsevii product sales were $6.0 million.
Ultragenyx
Ultragenyx
Ultragenyx Revenue by Segment
Forward Guidance
The Company continues to expect 2022 revenue for Crysvita in Ultragenyx territories to be between $250 million and $260 million and Dojolvi revenue to be between $55 million and $65 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income